Sign in
KRSA Stock Price, Chart, Stats & News
Korsana Biosciences, Inc.
Save
Korsana Biosciences, Inc. (KRSA) does not currently pay a dividend.
145.92M
Market cap
–
Current P/E
–
Forward P/E
KRSA chart
About
Korsana Biosciences, Inc. is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases. Its lead program, KRSA-028, is an investigational shuttled antibody targeting amyloid beta for the treatment of Alzheimer's disease. The company became publicly traded in September 2026 through a merger with Cyclerion Therapeutics, Inc.
Similar securities
Based on sector and market capitalization
Report issue